MED News & Events

Sees Q2 revenue $60M-$80M, one estimate $74.7M

Sees FY26 revenue $270M-$300M, one estimate $273.7M

Reports Q1 revenue $76.0M, one estimate $69.2M. "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been leading indicators of future growth. Backed by our differentiated science, coach-led model, and a disciplined approach to managing costs, we believe we are well positioned to drive improved performance through the remainder of 2026 and a return to sustainable, long-term growth in the years ahead," said Dan Chard, CEO of Medifast.

Medifast announced the company's board of directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners as independent director candidates to stand for election at the company's 2026 annual meeting of stockholders, which is provisionally scheduled for May 19. These nominations are pursuant to a cooperation agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the company's outstanding shares. The board of directors has determined that Medifast's directors Jeffrey Brown and Michael Hoer will not stand for reelection. Medifast chairman and CEO Dan Chard will continue in his current role, and as previously announced, will step down as CEO on June 1, while remaining chairman. Nicholas Johnson, president of Medifast, is expected to succeed Dan Chard as CEO following his departure.